Navigation Links
Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:11/1/2011

PALO ALTO, Calif., Nov. 1, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today the presentation of mechanistic studies on Telintra and related analogs at the 2011 Meeting of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California.  Details of the presentation are as follows:


  • Novel Ezatiostat analogues disrupt binding of GSTP1 to all three major MAP kinases (JNK, ERK and p38) and exhibit context-dependent antitumor activity; Ali-Osman, F., Okamura, T., Turley, R., Barker, A.,  Keck, J.,  Laborde, E.,  Cai, D.,  Macsata, R.Abstract B229 – PO 70, Therapeutic Agents: Small Molecule Kinase Inhibitors 2, Monday, November 14, 12:30-2:30 PM and 6:00-7:30 PM.These studies were conducted by Professor Francis Ali-Osman, Director, Experimental Therapeutics Program, Duke Comprehensive Cancer Center, and expand our understanding of the novel mechanism of action of Telintra.  Telintra and related analogues, through their inhibition of the enzyme GSTP1, were able to affect the activity of all three major MAP kinases, signaling proteins that are critical for the control of cellular growth, differentiation and apoptosis.  Significant anti-tumor activity was also observed in human cancer cells derived from brain cancer, breast cancer and melanoma.  Telintra has demonstrated positive clinical activity in patients with myelodysplastic syndrome (Blood 2009, 113[26]:6533-6540; Cancer 2011, doi: 10.1002/cncr.26469), and is currently in clinical development (Clintrials.gov).

    About Telik

    Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

    Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


    '/>"/>

  • SOURCE Telik, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
    2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
    3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
    4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
    5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
    6. Telik Announces Presentation at ASCO Annual Meeting
    7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
    8. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
    9. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
    10. Telik Announces Third Quarter 2009 Financial Results
    11. Telik Announces Fourth Quarter and 2009 Year End Financial Results and 2010 Financial Guidance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
    (Date:3/27/2017)... Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
    (Date:3/27/2017)... Calif. , March 27, 2017  Cryoport, Inc. ... that it intends to offer shares of common stock ... registration statement on file with the Securities and Exchange ... and other conditions, and there can be no assurance ... completed, or as to the actual size or terms ...
    Breaking Medicine Technology:
    (Date:3/28/2017)... San Diego, CA (PRWEB) , ... March 28, 2017 , ... ... and turtlenecks from the daily wardrobe. However, for those self-conscious about a double chin, ... believe they have the ideal solution. , “For most people, a double chin ...
    (Date:3/28/2017)... ... 2017 , ... Qualidigm , the mission-driven national healthcare ... new, more expansive office space in order to accommodate its growing number of ... building in Wethersfield, Conn. located at 936 Silas Deane Highway and immediately began ...
    (Date:3/28/2017)... ... March 28, 2017 , ... ... the Self-Funding Success website has recently developed and published an informational resource that ... was created based on common inquiries the site’s team of third party administrator ...
    (Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... will be offered by the American Association of Integrative Medicine and available for ... healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , Ed Arranga, ...
    (Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... With expansion ... Marshallville, Georgia, in early March. , The seed processing plant opened in Marshallville in ... since 2016. The new office allows opportunity for transition of Patten Seed operations to ...
    Breaking Medicine News(10 mins):